

2.2.7 Cancer of the pancreas

Cancer of the pancreas is the seventh leading cause of cancer death worldwide ([Ferlay et al., 2015](#)). Even in developed countries, few individuals diagnosed with pancreatic cancer survive more than 5 years ([Sirri et al., 2016](#)). Pancreatic cancer incidence and mortality rates have been increasing both in the USA ([Kohler et al., 2015](#)) and in western Europe ([Bosetti et al., 2013](#)), despite declines in cigarette smoking, an established risk factor for pancreatic cancer. It has been suggested that these increases may be at least partly attributable to increases in the prevalence of obesity ([Ma & Jemal, 2013](#)). Notably, type 2 diabetes mellitus, which is caused by obesity, is also an established risk factor for pancreatic cancer, and the incidence of diabetes is also increasing.

The great majority (> 85%) of pancreatic tumours are ductal adenocarcinomas and derive from the exocrine component of the pancreas. Other pancreatic tumours are a more heterogeneous collection of different tumour types and include, among others, acinar cell carcinoma of the pancreas (about 5% of exocrine pancreatic cancers), cystadenocarcinomas, adenosquamous carcinomas, pancreatic mucinous cystic neoplasms, and pancreatic neuroendocrine (islet cell) tumours (1–2% of all pancreatic cancers).

In 2001, the Working Group of the *IARC Handbook* on weight control and physical activity ([IARC, 2002](#)) concluded that the evidence of an association between avoidance of weight gain and pancreatic cancer was *inadequate*. Because of the high case fatality of pancreatic cancer, results from studies of pancreatic cancer incidence and mortality can be considered comparable. Results from individual cohort studies with more than 100 cases of pancreatic cancer ([Table 2.2.7a](#)), from case-control studies ([Table 2.2.7b](#)), and from

meta-analyses or pooled analyses ([Table 2.2.7c](#)) are summarized in this section.

(a) Cohort studies

Since 2000, more than 30 individual cohort studies including pooled analyses have reported on the associations of excess body fatness with pancreatic cancer incidence or mortality ([Table 2.2.7a](#)). In addition, seven meta-analyses of cohort studies have been published since then ([Table 2.2.7c](#)).

BMI, usually ascertained at study enrolment at or after middle age, was by far the most common measure of excess body weight examined in these cohort studies. In a comprehensive meta-analysis by the WCRF Continuous Update Project that included 23 cohort studies of pancreatic cancer incidence and more than 9500 incident cases of pancreatic cancer, the summary relative risk for a continuous 5 kg/m² increase in BMI was 1.10 (95% CI, 1.07–1.14), with similar results in men and in women ([WCRF/AICR, 2012](#)). Other meta-analyses or pooled cohort studies, all with considerable overlap in study populations, have reported similar results per 5 kg/m² increase in BMI ([Larsson et al., 2007](#); [Renehan et al., 2008](#); [Genkinger et al., 2011, 2015](#)).

The largest study that presented categorical BMI results was an analysis that included nearly 6000 pancreatic cancer deaths in White men and women in the Cancer Prevention Study II ([Arnold et al., 2009](#)). In that analysis, obesity (i.e. BMI ≥ 30 kg/m²) was associated on average with a 40% higher risk of pancreatic cancer mortality compared with normal BMI (18.5– < 25 kg/m²), and results were similar in men and in women separately. [No associations were found in Black men and women, but the sample size was very small compared with the group of White men and women.]

Relatively few large studies of BMI and pancreatic cancer have been conducted in populations that were not predominantly of European descent. Relative risks from the largest study in

African Americans, a pooled analysis of seven cohorts ([Bethea et al., 2014](#)), and from a study in the Republic of Korea with 1860 cases ([Jee et al., 2008](#)), the largest in an Asian population, appear consistent with those observed in meta-analyses of populations of Caucasians. However, BMI was not associated with risk of pancreatic cancer in a pooled analysis of the Asia Cohort Consortium ([Lin et al., 2013b](#)).

Some evidence suggests that the association between BMI and pancreatic cancer may differ by smoking status. In the large NIH-AARP cohort, there was a statistically significant interaction between BMI and smoking status, with a positive association between BMI and risk of pancreatic cancer in never-smokers and in former smokers but not in current smokers ([Stolzenberg-Solomon et al., 2013](#)). Similarly, increased BMI was associated with higher risk of pancreatic cancer in never-smokers and in former smokers in other studies, although these interactions were not statistically significant ([Genkinger et al., 2011](#); [Aune et al., 2012](#)).

A limited number of individual cohort studies have examined the association between BMI in early adulthood, usually defined as age 18–21 years, and pancreatic cancer incidence or mortality ([Patel et al., 2005](#); [Lin, et al., 2007](#); [Verhage et al., 2007](#); [Stolzenberg-Solomon et al., 2013](#)), with mixed results. [These studies calculated BMI in early adulthood based on weight in young adulthood recalled by participants who were middle-aged or older.]

The largest analysis of BMI in early adulthood, as well as BMI change after early adulthood in relation to pancreatic cancer mortality, is a pooled analysis including more than 3000 pancreatic cancer deaths from 14 cohorts ([Genkinger et al., 2015](#)). In that pooled analysis, an increase of 5 kg/m² in BMI in early adulthood was associated with a relative risk of 1.18 (95% CI, 1.11–1.25), and BMI change after early adulthood was also significantly associated with increased

risk (RR per 5 kg/m² increase, 1.05, 95% CI, 1.01–1.10).

Several other individual cohort studies examined associations of change in weight ([Samanic et al., 2006](#), [Lin et al., 2007](#), [Luo et al., 2008](#), [Johansen et al., 2009](#)) or change in BMI ([Verhage et al., 2007](#)) with risk of pancreatic cancer. None of these studies reported statistically significant associations, except for a study in Sweden that found higher risk in a small group of men with a weight increase of 15% or more in 6 years ([Samanic et al., 2006](#)) and another study that reported significant positive associations in a small group of men with a BMI increase of 8 kg/m² or more since age 20 years ([Verhage et al., 2007](#)).

Several individual cohort studies have examined associations of waist circumference with risk of pancreatic cancer ([Larsson et al., 2005](#); [Berrington de González et al., 2006](#); [Luo et al., 2008](#); [Stolzenberg-Solomon et al., 2008](#)). In the WCRF meta-analysis, the relative risk per 10 cm increase in waist circumference was 1.11 (95% CI, 1.05–1.18) ([WCRF/AICR, 2012](#)). In addition, waist circumference was examined in a large pooled analysis of pancreatic cancer mortality including data from 11 cohort studies ([Genkinger et al., 2015](#)); a higher waist circumference was associated with increased risk of pancreatic cancer mortality (RR per 10 cm increase, 1.07; 95% CI, 1.00–1.14), and no differences in risk were observed between men and women.

(b) Case-control studies

A total of 15 independent case-control studies, conducted in Canada, China, Europe, Japan, North Africa (Egypt), and the USA, reported on the association of BMI with cancer of the pancreas ([Table 2.2.7b](#)). In all studies, the assessment of BMI was based on self-reported height and usual body weight or body weight during a relatively recent time frame before cancer diagnosis. In a few studies, additional self-reports were also obtained for body weight

up to 20 years before cancer diagnosis, or body weight at various pre-specified ages in the more distant past. In all but two studies ([Pezzilli et al., 2005](#); [Lo et al., 2007](#)), the estimated association of BMI with risk of pancreatic cancer was adjusted for smoking, as well as for various other potential confounding factors.

For usual BMI before disease onset, 7 of the 14 studies reported statistically significant increases in risk, either overall or in sex-stratified analyses ([Silverman et al., 1998](#); [Hanley et al., 2001](#); [Eberle et al., 2005](#); [Anderson et al., 2009](#); [Li et al., 2009](#); [Halfdanarson et al., 2014](#); [Zheng et al., 2016](#)).

Of the remaining studies, the majority showed odds ratios above 1.0. In studies presenting sex-stratified analyses, positive associations with BMI appeared to be somewhat stronger and more often significant for men than for women ([Hanley et al., 2001](#); [Silverman, 2001](#); [Eberle et al., 2005](#); [Fryzek et al., 2005](#); [Li et al., 2009](#)).

The study by [Fryzek et al. \(2005\)](#) in the USA showed inverse associations of current BMI (at diagnosis) and cancer of the pancreas and no association with BMI 5 years before interview. However, analyses based on recalled BMI 20 years before interview showed a statistically significant direct association with risk of pancreatic cancer, although in men only. In a similar type of analysis, a case-control study in the Czech Republic and Slovakia ([Urayama et al., 2011](#)) also showed a statistically significant association of pancreatic cancer with recalled BMI at age 20 years and at age 40 years, but not with BMI 2 years before interview (OR, 0.98; 95% CI, 0.85–1.13).

In two studies, associations of BMI with risk of pancreatic cancer were estimated separately for never-smokers and ever-smokers.

In the USA, [Fryzek et al. \(2005\)](#) reported a statistically significant and up to 3.3-fold increase in risk of pancreatic cancer (95% CI, 1.2–9.2) only in never-smokers in the highest category of BMI compared with those with low BMI, and no relationship was found in smokers.

A second study, also in the USA ([Li et al., 2009](#)), reported a positive association of BMI with risk of pancreatic cancer both in ever-smokers (OR per 5 kg/m² increase, 1.75; 95% CI, 1.37–2.22) and in never-smokers (OR, 1.46; 95% CI, 1.16–1.84).

One case-control study in the USA (with 309 cases and 602 controls) specifically addressed the association of BMI with pancreatic neuroendocrine tumours, a rare pancreatic cancer tumour, and observed an increased risk in individuals who were obese (BMI \geq 30 kg/m²) compared with those with a lower BMI (OR, 1.65; 95% CI, 1.11–2.45) ([Halfdanarson et al., 2014](#)).

Table 2.2.7a Cohort studies of measures of body fatness and cancer of the pancreas

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Friedman & van den Eeden (1993) Nested case-control study within Kaiser Permanente USA 1964–1988	450 cases, 2687 controls Men and women Incidence	Pancreas	BMI, per 1 kg/m ² increase Weight, per 5 kg	450	1.02 (1.00–1.04) 1.06 (1.01–1.11)	Age, cigarette smoking, race	
Gapstur et al. (2000) Chicago Heart Association Detection Project in Industry Cohort USA 1967–1995	20 475 Men Mortality 15 183 Women Mortality	Pancreas ICD-8: 157	BMI < 24.129 24.129–26.292 26.293–28.630 ≥ 28.631 BMI < 20.978 20.978–23.240 23.241–26.156 ≥ 26.157	10 21 23 42 9 6 16 12	1.00 1.76 (0.83–3.74) 1.68 (0.80–3.53) 3.04 (1.52–6.08) 1.00 0.48 (0.17–1.26) 1.09 (0.47–2.51) 0.73 (0.30–1.80)	Age Age	
Isaksson et al. (2002) Swedish Twin Registry Sweden 1969–1997	21 884 Men and women Incidence	Pancreas	BMI < 18.5 18.5–24.99 25–30 > 30	5 84 70 4	2.30 (0.93–5.71) 1.00 1.36 (0.99–1.88) 0.56 (0.20–1.52)	Age, sex, smoking	No associations were observed for adult weight gain (in kg)
Samanic et al. (2004) United States Veterans cohort USA 1969–1996	4 500 700 Men Incidence	Pancreas ICD-9: 157	Obesity Non-obese Obese Non-obese Obese	White men: 5483 391 Black men: 1638 83	1.00 1.20 (1.07–1.33) 1.00 1.07 (0.86–1.34)	Age, calendar year	Obesity defined as discharge diagnosis of obesity: ICD-8: 277; ICD-9: 278.0

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Batty et al. (2005) Whitehall Study United Kingdom 1967–2002	18 403 Men Mortality	Pancreas ICD-8/9: 157 ICD-10: C25	BMI 18.5–24.9 25.0–29.9 ≥ 30 [<i>P</i> _{trend}]	75 69 3	1.00 1.18 (0.83–1.68) 0.58 (0.18–1.91) [0.80]	Age, employment grade, physical activity, smoking, marital status, prevalent disease, weight loss in past year, BP medication, height, skinfold thickness, systolic BP, plasma cholesterol, glucose intolerance, diabetes	
Larsson et al. (2005) Swedish Mammography Cohort (SMC) Sweden 1987–2004 Cohort of Swedish Men (COSM) Sweden 1997–2004	83 053 Men and women Incidence	Pancreas ICD-9: 157, excluding 157.4	BMI < 20 20–24.9 25–29.9 ≥ 30 [<i>P</i> _{trend}] WC (cm), quartiles (sex-specific) Men: < 90 90–94 95–101 ≥ 102 [<i>P</i> _{trend}] Women: < 76 76–81 82–89 ≥ 90	5 50 54 19 16 20 34 36	0.96 (0.38–2.46) 1.00 1.25 (0.84–1.86) 1.81 (1.04–3.15) [0.04] 1.00 1.15 (0.59–2.25) 1.59 (0.87–2.93) 1.72 (0.93–3.20) [0.05]	Age, education level, physical activity, smoking, alcohol consumption, sex	In stratified analyses, stronger associations with BMI in men than in women

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Patel et al. (2005) Cancer Prevention Study II (CPS II) Nutrition Cohort 1992–1999	145 627 Men and women Incidence and mortality	Pancreas ICD-9: 157.0–157.9 ICD-10: C25.0–25.9	BMI at baseline			Age, smoking, years since quitting smoking, education level, family history of pancreatic cancer, gall bladder disease, diabetes, height, energy intake, physical activity	In stratified analyses, association with BMI at baseline was stronger in men than in women
			< 25	50	1.00		
			25–29.9	33	1.03 (0.76–1.38)		
			≥ 30	22	2.08 (1.48–2.93) [0.0001]		
			[<i>P</i> _{trend}]				
			BMI at age 18 yr				
			< 21	59	1.00		
			21–22.9	25	1.07 (0.77–1.49)		
			≥ 23	17	1.33 (0.95–1.85) [0.11]		
			[<i>P</i> _{trend}]				
Adult weight change (kg)							
< –2.27	4	1.74 (0.94–3.22)					
–2.27 to 4.54	20	1.00					
4.55–9.07	18	1.12 (0.70–1.79)					
9.08–13.61	21	0.97 (0.60–1.58)					
≥ 13.62	38	0.96 (0.61–1.52) [0.16]					
[<i>P</i> _{trend}]							
Sinner et al. (2005) Iowa Women’s Health Study USA 1986–2001	28 002 Women Incidence	Pancreas ICD-10: C25	BMI			Age, smoking status, multivitamin use	
			< 25	84	1.00		
			25–29.9	72	0.94 (0.69–1.29)		
			≥ 30	53	1.14 (0.81–1.62)		
Berrington de González et al. (2006) EPIC cohort 10 European countries 1991–2004	438 405 Men and women Incidence	Pancreas	BMI			Sex, smoking, diabetes Weight and WC estimates also adjusted for height	
			< 20	9	0.67 (0.33–1.37)		
			20–22.9	48	1.00		
			23–24.9	85	0.99 (0.69–1.41)		
			25–26.9	71	0.82 (0.56–1.19)		
			27–29.9	43	0.76 (0.50–1.16)		
			30–34.9	50	1.16 (0.77–1.76)		
			≥ 35	13	1.19 (0.64–2.23)		
			per 5 kg/m ²		1.09 (0.95–1.24) [0.24]		
[<i>P</i> _{trend}]							

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Berrington de González et al. (2006) (cont.)			Weight (kg), quartiles (sex-specific) Men: Women: < 73 < 58 73–79 58–63 80–87 64–71 ≥ 88 ≥ 72 per 5 kg [P _{trend}]	66 65 85 103	1.00 0.90 (0.63–1.28) 1.02(0.73–1.44) 1.14 (0.82–1.61) 1.05 (0.99–1.10) [0.06]		
			WC (cm), quartiles (sex-specific) Men: Women: < 88 < 73 88–93 73–78 94–100 79–87 ≥ 101 ≥ 88 per 10 cm [P _{trend}]	51 59 79 91	1.00 0.96 (0.65–1.41) 1.05(0.72–1.53) 1.33 (0.93–1.92) 1.24 (1.04–1.48) [0.03]		
Samanic et al. (2006) Swedish Construction Worker Cohort Sweden 1958–1999	362 552 (107 815 in weight change analysis) Men Incidence	Pancreas ICD-7: 157	BMI 18.5–24.9 25–29.9 ≥ 30 [P _{trend}] 6-yr weight change –4% to +4.9% 5–9.9% 10–14.9% ≥ 15% [P _{trend}]	352 289 57 86 41 13 7	1.00 0.95 (0.82–1.12) 1.16 (0.87–1.53) [> 0.5] 1.00 1.45 (1.00–2.11) 1.53 (0.85–2.77) 2.67 (1.22–5.84) [> 0.5]	Attained age, calendar year, smoking	

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Lin et al. (2007) JACC cohort Japan 1988–2003	43 579 Men Mortality	Pancreas ICD-10: C25	BMI at baseline			Age, smoking, diabetes, gall bladder disease	
			< 20	46	1.12 (0.76–1.63)		
			20–22.4	71	1.00		
			22.5–24.9	57	0.94 (0.66–1.34)		
			25–27.4	26	1.02 (0.65–1.62)		
			27.5–29.9	6	0.62 (0.23–1.70)		
			≥ 30	1	0.58 (0.08–4.16)		
			[P _{trend}]		[0.47]		
			BMI at age 20 yr				
			< 20	27	1.39 (0.86–2.24)		
	20–22.4	45	1.00				
	22.5–24.9	45	1.13 (0.75–1.71)				
	25–27.4	21	1.54 (0.92–2.58)				
	27.5–29.9	6	1.65 (0.70–3.86)				
	≥ 30	4	3.51 (1.26–9.78)				
	[P _{trend}]		[0.01]				
	Weight change (kg)						
	< -5	45	1.63 (1.05–2.53)				
	-5 to < 0	22	1.39 (0.82–2.33)				
	0	47	1.00				
> 0–4.9	12	1.11 (0.58–2.12)					
≥ 5	21	0.85 (0.49–1.47)					
59 107 Women Mortality	Pancreas ICD-10: C25	BMI at baseline			Age, smoking, diabetes, gall bladder disease		
		< 20	33	1.15 (0.74–1.80)			
		20–22.4	50	1.00			
		22.5–24.9	62	1.33 (0.91–1.95)			
		25–27.4	30	1.21 (0.77–1.92)			
		27.5–29.9	16	1.57 (0.86–2.86)			
		≥ 30	4	1.04 (0.37–2.89)			
		[P _{trend}]		[0.28]			

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Lin et al. (2007) (cont.)			BMI at age 20 yr < 20 20–22.4 22.5–24.9 25–27.4 27.5–29.9 ≥ 30 [<i>P</i> _{trend}] Weight change (kg) < -5 -5 to < 0 0 > 0–4.9 ≥ 5	25 51 48 15 3 1	0.81 (0.50–1.31) 1.00 1.08 (0.73–1.61) 0.69 (0.39–1.23) 0.46 (0.14–1.48) 0.43 (0.06–3.15) [0.09]		
Luo et al. (2007) Japan Public Health Center Prospective Study Japan 1990–2003	47 499 Men Incidence 52 161 Women Incidence	Pancreas ICD-10: C25	BMI 14–20.9 21–24.9 25–40 [<i>P</i> _{trend}] BMI 14–20.9 21–24.9 25–40 [<i>P</i> _{trend}]	37 69 22 14 49 33	1.4 (0.8–2.5) 1.0 0.7 (0.4–1.1) [0.01] 0.7 (0.4–1.3) 1.0 1.1 (0.7–1.6) [0.3]	Smoking, diabetes, physical activity, study area, age, alcohol use, history of cholelithiasis	
Máchová et al. (2007) National Cancer Registry, nested case–control study Czech Republic 1987–2002	17 110 Men Incidence 20 856 Women Incidence	Pancreas ICD-10: C25	BMI 18.5–24.9 25–29.9 ≥ 30 BMI 18.5–24.9 25–29.9 ≥ 30	114 total 80 total	1.00 1.24 (0.74–2.07) 1.81 (0.98–3.31) 1.00 0.68 (0.37–1.26) 0.95 (0.50–1.79)	Age, smoking, hypertension, height	Nested case–control study, reporting odds ratios

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Nöthlings et al. (2007) Multiethnic Cohort Study USA 1993–2002	77 255 Men Incidence	Pancreas ICD-10: C25.0–25.3, C25.7–25.9	BMI			Ethnicity, smoking, family history of pancreatic cancer, diabetes, age, energy intake, intake of red meat, intake of processed meat, physical activity	
			< 25	110	1.00		
			25–29.9	89	0.99 (0.74–1.33)		
	≥ 30	38	1.51 (1.02–2.26)				
	[<i>P</i> _{trend}]		[0.085]				
	90 175 Women Incidence		BMI				
< 25	52	1					
25–29.9	62	0.80 (0.59–1.09)					
≥ 30	62	0.65 (0.43–0.99)					
[<i>P</i> _{trend}]		61	[0.031]				
Verhage et al. (2007) Netherlands Cohort Study on Diet and Cancer The Netherlands 1986–1999	2366 Men Incidence	Pancreas ICD-10: C25	BMI at baseline			Age, smoking, diabetes, hypertension	When restricting to microscopically confirmed exocrine pancreatic cancer, significant positive associations were found with increased BMI and weight at baseline, and with BMI change since age 20 yr
			< 23	44	1.10 (0.72–1.69)		
			23–24.9	67	1.00		
			25–26.9	50	0.93 (0.61–1.39)		
			27–29.9	39	1.17 (0.75–1.81)		
			≥ 30	20	2.69 (1.47–4.92)		
			[<i>P</i> _{trend}]		[0.141]		
			per 1 kg/m ²		1.05 (0.99–1.12)		
			BMI at age 20 yr				
			< 20	35	1.00		
			20–20.9	26	0.80 (0.46–1.40)		
			21–22.9	60	0.99 (0.62–1.59)		
			≥ 23	52	1.07 (0.67–1.73)		
			[<i>P</i> _{trend}]		[0.56]		
			per 1 kg/m ²		1.03 (0.96–1.10)		
BMI change since age 20 yr							
< 0	14	0.99 (0.53–1.85)					
0–3.9	84	1.00					
4–7.9	60	1.34 (0.90–1.99)					
≥ 8	15	2.21 (1.09–4.49)					
[<i>P</i> _{trend}]		[0.052]					
per 1 kg/m ²		1.07 (0.99–1.15)					

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments	
Verhage et al. (2007) (cont.)	2438 Women Incidence	Pancreas ICD-10: C25	Weight at baseline (kg)					
			< 65	74	1.00			
			65–69	47	1.16 (0.76–1.76)			
			70–74	46	1.13 (0.75–1.70)			
			75–79	21	0.92 (0.53–1.59)			
			≥ 80	36	1.55 (0.99–2.45)			
			[<i>P</i> _{trend}]		[0.18]			
			continuous per kg		1.01 (0.99–1.03)			
			BMI at baseline					
			< 23	46	1.02 (0.66–1.58)		Age, smoking, diabetes, hypertension	When restricting to microscopically confirmed exocrine pancreatic cancer, significant positive associations were found with increased weight at baseline and with BMI change since age 20 yr. A significant <i>P</i> _{trend} was also observed with increased BMI at baseline
			23–24.9	45	1.00			
			25–26.9	55	1.69 (1.11–2.58)			
			27–29.9	38	1.41 (0.89–2.25)			
			≥ 30	19	1.31 (0.74–2.31)			
			[<i>P</i> _{trend}]		[0.052]			
			per 1 kg/m ²		1.04 (1.00–1.08)			
			BMI at age 20 yr					
< 20	65	1.00						
20–20.9	27	0.93 (0.58–1.51)						
21–22.9	42	0.69 (0.46–1.04)						
≥ 23	52	0.97 (0.66–1.44)						
[<i>P</i> _{trend}]		[0.535]						
per 1 kg/m ²		1.02 (0.95–1.09)						
BMI change since age 20 yr								
< 0	15	0.67 (0.37–1.21)						
0–3.9	76	1.00						
4–7.9	63	1.08 (0.75–1.55)						
≥ 8	31	1.72 (1.11–2.67)						
[<i>P</i> _{trend}]	185	[0.004]						
per 1 kg/m ²		1.05 (1.01–1.10)						

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Verhage et al. (2007) (cont.)			Weight at baseline (kg)				
			< 65	59	1.00		
			65–69	42	1.23 (0.81–1.88)		
			70–74	39	1.30 (0.84–1.99)		
			75–79	31	1.58 (0.99–2.52)		
			≥ 80	39	1.64 (1.07–2.52)		
			[<i>P</i> _{trend}]		[0.010]		
			continuous per kg		1.02 (1.01–1.03)		
Jee et al. (2008) National Health Insurance Corporation Republic of Korea 1992–2006	770 556 Men Incidence	Pancreas	BMI			Age, smoking	
			< 20.0	199	0.87 (0.71–1.08)		
			20.0–22.9	678	1.01 (0.87–1.16)		
			23.0–24.9	524	1.00		
			25.0–29.9	442	1.06 (0.90–1.24)		
			≥ 30.0	17	1.34 (0.75–2.38)		
			[<i>P</i> _{trend}]		[0.1139]		
	423 273 Women Incidence		BMI			Age, smoking	
			< 20.0	80	0.88 (0.62–1.24)		
			20.0–22.9	246	1.09 (0.84–1.40)		
			23.0–24.9	178	1.00		
			25.0–29.9	253	1.35 (1.05–1.74)		
			≥ 30.0	34	1.80 (1.14–2.86)		
			[<i>P</i> _{trend}]		[0.0014]		
Luo et al. (2008) Women’s Health Initiative USA 1993–2005	138 503 Women Incidence	Pancreas	BMI			Age, treatment assignments, cigarette smoking, diabetes	Study of postmenopausal women
			< 22.0	25	0.8 (0.5–1.2)		
			22.0–24.9	62	1.0		
			25.0–29.9	84	0.9 (0.6–1.2)		
			30.0–34.9	56	1.1 (0.7–1.5)		
			≥ 35.0	24	0.8 (0.5–1.3)		
			[<i>P</i> _{trend}]		[0.9]		

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Luo et al. (2008) (cont.)			WC (cm), quintiles (range, median) 35.0–74.5, 70.5 74.6–81.0, 78.0 81.1–88.0, 85.0 88.1–97.4, 92.4 97.5–194.2, 105.0 [<i>P</i> _{trend}] per 10 cm Type of weight change: Stable weight Steady gain in weight Lost weight and kept it off Weight up and down (> 10 lb)	41 50 46 63 51	1.0 1.1 (0.7–1.7) 1.0 (0.7–1.6) 1.4 (0.9–2.0) 1.1 (0.7–1.6)		
Stolzenberg-Solomon et al. (2008) NIH-AARP cohort USA 1995–2000	293 562 Men Incidence	Pancreatic adenocarcinoma ICD-10: C25.0–25.9 Excludes endocrine tumours	BMI 18.5– < 25.0 25.0–29.9 30.0–34.9 ≥ 35.0 [<i>P</i> _{trend}] WC (cm) < 88.9 88.9–93.3 93.3–98.4 98.4–106 ≥ 106 [<i>P</i> _{trend}]	110 227 66 26	1.00 1.22 (0.97–1.54) 1.09 (0.80–1.48) 1.61 (1.05–2.49) [0.07]	Age, smoking, race, energy intake, energy-adjusted total fat intake, diabetes; for WC, also adjusted for BMI	
			WC (cm) < 88.9 88.9–93.3 93.3–98.4 98.4–106 ≥ 106 [<i>P</i> _{trend}]	40 35 39 46 52	1.00 1.00 (0.62–1.61) 0.81 (0.49–1.32) 0.96 (0.58–1.58) 0.95 (0.54–1.67) [0.91]		

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Stolzenberg-Solomon et al. (2008) (cont.)	201 473 Women Incidence		BMI				Age, smoking, race, energy intake, energy-adjusted total fat intake, diabetes; for WC, also adjusted for BMI
			18.5– < 25.0	84	1.00		
			25.0–29.9	84	1.33 (0.98–1.81)		
			30.0–34.9	38	1.40 (0.95–2.07)		
			35.0	19	1.29 (0.78–2.16)		
			[<i>P</i> _{trend}]		[0.09]		
			WC (cm)				
			< 74.9	14	1.00		
74.9–83.2	24	1.74 (0.89–3.41)					
83.2–92.1	28	1.88 (0.92–3.85)					
≥ 92.1	34	2.53 (1.13–5.65)					
			[<i>P</i> _{trend}]		[0.04]		
Arnold et al. (2009) Cancer Prevention Study II (CPS II) USA 1984–2004	48 525 Black men and women Mortality	Pancreas ICD-9: 157	BMI			Age, diabetes, family history of pancreatic cancer, cholecystectomy, smoking status; analysis for men and women also adjusted for sex	
			< 18.5	2	0.44 (0.11–1.77)		
			18.5–24.9	122	1.00		
	17 602 Black men Mortality		25–29.9	136	0.89 (0.70–1.40)		
			≥ 30	80	1.06 (0.80–1.42)		
			BMI				
	30 923 Black women Mortality		< 18.5	0	–		
			18.5–24.9	45	1.00		
			25–29.9	65	1.02 (0.69–1.49)		
	1 011 864 White men and women Mortality		≥ 30	33	1.66 (1.05–2.63)		
			BMI				
			< 18.5	2	0.60 (0.15, 2.44)		
			18.5–24.9	77	1.00		
25–29.9			71	0.82 (0.59–1.14)			
≥ 30			47	0.82 (0.56–1.18)			
		BMI					
		< 18.5	86	0.93 (0.75–1.16)			
		18.5–24.9	2644	1.00			
		25–29.9	2351	1.15 (1.08–1.22)			
		≥ 30	690	1.40 (1.28–1.52)			

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Arnold et al. (2009) (cont.)	444 351 White men Mortality		BMI				
			< 18.5	19	0.83 (0.53–1.31)		
			18.5–24.9	1080	1.00		
			25–29.9	1479	1.11 (1.02–1.20)		
	567 513 White women Mortality		BMI				
			< 18.5	67	0.97 (0.76–1.24)		
Johansen et al. (2009) Malmö Preventive Project Sweden 1974–2004	33 325 Men and women Incidence	Pancreas ICD-7: 157 ICD-10: C25	BMI				Age, sex, smoking, alcohol consumption
			< 20	10	0.84 (0.44–1.61)		
			20–24.9	101	1.00		
			25–29.9	54	0.83 (0.60–1.16)		
			≥ 30	18	1.38 (0.83–2.28)		
			continuous		1.04 (0.995–1.08)		
Meinhold et al. (2009) ATBC subcohort of non-diabetics Finland 1985–2004	27 035 Men Incidence	Pancreas ICD-9: 157, excluding 157.4	BMI, quartiles				Age, smoking, energy intake, diabetes mellitus (self-reported)
			Q1	117	1.00		
			Q2	139	0.97 (0.76–1.24)		
			Q3	41	1.03 (0.72–1.47)		
			Q4	8	1.42 (0.69–2.93)		
			continuous [P_{trend}]		1.01 (0.94–1.08) [0.80]		
Stevens et al. (2009) Million Women Study USA 1996–2006	1.29 million Women Incidence	Pancreas ICD-10: C25	BMI		RR (floating SE)	Age, region, SES, smoking, height	
			< 22.5	246	1.02 (0.07)		
			22–24.9	311	1.00 (0.06)		
			25–27.4	260	0.99 (0.06)		
			27.5–29.9	188	1.17 (0.09)		
			30–32.4	119	1.27 (0.12)		
≥ 32.5	152	1.42 (0.12)					

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Stevens et al. (2009) (cont.)	1.29 million Women Mortality		BMI < 22.5 22–24.9 25–27.4 27.5–29.9 30–32.4 ≥ 32.5		RR (floating SE) 334 1.08 (0.06) 400 1.00 (0.05) 347 1.03 (0.05) 227 1.09 (0.07) 139 1.14 (0.10) 188 1.36 (0.10)	Age, region, SES, smoking, height	
Whitlock et al. (2009) Pooled analysis of 57 cohort studies Europe, Japan, and USA Follow-up varied by cohort	894 576 Men and women Mortality	Pancreas ICD-9: 157	BMI, per 5 kg/m ² For BMI 15–25 For BMI 25–50 For BMI 15–50		470 0.87 (0.65–1.17) 520 1.04 (0.86–1.25) 1.07 (0.97–1.19)	Study, sex, age, baseline smoking	
Arslan et al. (2010) Pancreatic Cancer Cohort Consortium (PanScan) pooled analysis, nested case–control Follow-up varies by cohort	2170 (men: 1059; women: 1111) Incidence	Pancreas	BMI < 18.5 ≥ 18.5– < 25.0 ≥ 25– < 30 ≥ 30– < 35 ≥ 35 [P _{trend}]		19 0.84 (0.44–1.59) 759 1.00 868 1.15 (1.00–1.33) 325 1.13 (0.93–1.37) 124 1.26 (0.93–1.71) [0.047]	Cohort, age, sex, anthropometry source, smoking, diabetes history	Non-significant positive associations were observed with WC (P _{trend} = 0.09)
Jiao et al. (2010) Pooled analysis of 7 cohort studies Follow-up varies by cohort	943 759 Men and women Incidence	Pancreatic adenocarcinoma ICD-10: C25 excluding C25.4 ICD-8/9: 157 excluding 157.4	BMI 16.5–18.4 18.5–24.9 25–29.9 30–34.9 ≥ 35 [P _{trend}] per 5 kg/m ²		17 0.89 (0.55–1.44) 855 1.00 1109 1.13 (1.03–1.23) 381 1.19 (1.05–1.35) 92 1.19 (0.96–1.48) [0.001] 1.08 (1.03–1.14)	Age, sex, cohort, smoking	

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Jiao et al. (2010) (cont.)	458 070 Men Incidence		BMI 16.5–18.4 18.5–24.9 25–29.9 30–34.9 ≥ 35 [P _{trend}] per 5 kg/m ²	7 465 793 240 43	0.88 (0.42–1.86) 1.00 1.11 (0.99–1.25) 1.11 (0.95–1.30) 1.34 (0.98–1.84) [0.03] 1.05 (0.98–1.12)		
	485 689 Women Incidence		BMI 16.5–18.4 18.5–24.9 25–29.9 30–34.9 ≥ 35 [P _{trend}] per 5 kg/m ²	10 390 316 141 49	0.91 (0.48–1.70) 1.00 1.15 (0.99–1.34) 1.34 (1.11–1.64) 1.09 (0.81–1.47) [0.01] 1.12 (1.05–1.19)		
Parr et al. (2010) Pooled analysis of 39 cohort studies Asia, Australia, and New Zealand 1961–1999, median follow-up 4 yr	326 387 Men and women Mortality	Pancreas ICD-9: 157 ICD-10: C25	BMI < 18.5 18.5–24.9 25–29.9 ≥ 30 per 5 kg/m ² [P _{trend}]	11 114 65 90 21	0.71 (0.38–1.31) 1.00 (0.86–1.16) 0.93 (0.75–1.15) 0.75 (0.48–1.18) 0.93 (0.78–1.11) [0.24]	Age, sex, smoking	
Genkinger et al. (2011) Pooling project of prospective studies of diet and cancer (14 cohort studies)	Women: 531 755 Men: 314 585 Incidence and mortality	Pancreas	BMI at baseline < 21 21–22.9 23–24.9 25–29.9 ≥ 30 [P _{trend}] per 5 kg/m ²	All: 196 290 457 847 345	1.16 (0.96–1.40) 1.00 1.07 (0.92–1.25) 1.18 (1.03–1.36) 1.47 (1.23–1.75) [< 0.001] 1.14 (1.07–1.21)	Smoking, diabetes, alcohol consumption, energy intake, age, baseline year	No statistically significant interaction by sex was found for BMI at baseline, BMI in early adulthood, or BMI change

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/ mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Genkinger et al. (2011) (cont.)	Women: 531 755 Men: 314 585 Incidence and mortality	Pancreas	BMI at baseline	Women:			
			< 21	148	1.15 (0.92–1.44)		
			21–22.9	177	1.00		
			23–24.9	221	1.08 (0.88–1.32)		
			25–29.9	378	1.29 (1.04–1.61)		
			≥ 30	192	1.46 (1.17–1.80)		
			[P _{trend}]		[0.002]		
			per 5 kg/m ²		1.13 (1.06–1.21)		
			BMI at baseline	Men:			
			< 21	48	1.19 (0.85–1.68)		
			21–22.9	113	1.00		
			23–24.9	236	1.07 (0.85–1.34)		
			25–29.9	469	1.09 (0.88–1.34)		
			≥ 30	153	1.50 (1.07–2.11)		
			[P _{trend}]		[0.06]		
			per 5 kg/m ²		1.14 (1.01–1.29)		
			BMI in early adulthood	All:			
< 18.5	163	0.95 (0.79–1.15)					
18.5–20.9	519	0.99 (0.87–1.13)					
21–22.9	426	1.00					
23–24.9	276	1.09 (0.92–1.29)					
≥ 25	214	1.21 (1.01–1.45)					
[P _{trend}]		[0.03]					
per 5 kg/m ²		1.20 (1.10–1.30)					
BMI in early adulthood	Women:						
< 18.5	121	0.92 (0.70–1.21)					
18.5–20.9	351	0.96 (0.81–1.14)					
21–22.9	239	1.00					
23–24.9	113	0.98 (0.78–1.24)					
≥ 25	94	1.16 (0.90–1.50)					
[P _{trend}]		[0.18]					
per 5 kg/m ²		1.14 (1.02–1.28)					

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Genkinger et al. (2011) (cont.)	Women: 531 755 Men: 314 585 Incidence and mortality	Pancreas	BMI in early adulthood < 18.5 18.5–20.9 21–22.9 23–24.9 ≥ 25 [P _{trend}] per 5 kg/m ² BMI change < -2 -2 to +2 2–5 5–10 > 10 [P _{trend}]	Men: 42 168 187 163 120 All: 79 391 493 491 144	1.02 (0.72–1.45) 1.03 (0.78–1.35) 1.00 1.19 (0.87–1.62) 1.21 (0.88–1.68) [0.06] 1.27 (1.12–1.44) 1.44 (1.13–1.85) 1 0.98 (0.85–1.12) 1.13 (0.98–1.30) 1.40 (1.13–1.72) [0.04]		
Klein et al. (2013) Pancreatic Cancer Cohort Consortium (PanScan)	3349 Men and women Incidence	Pancreas	BMI < 18.5 18.5–24.9 25–30 > 30	NR	0.91 (0.54–1.53) 1.00 1.08 (0.96–1.22) 1.26 (1.09–1.45)	Sex, age, study	
Lin et al. (2013b) Pooled analysis of 16 cohort studies from Asia Cohort Consortium Follow-up varies by cohort	799 542 Men and women Mortality	Pancreas	BMI < 18.5 18.5–19.9 20–22.4 22.5–24.9 25–27.4 27.5–29.9 ≥ 30	All: 116 130 432 454 232 89 36	1.04 (0.84–1.30) 0.82 (0.67–1.00) 0.91 (0.80–1.05) 1.00 0.95 (0.80–1.11) 1.01 (0.80–1.29) 0.96 (0.67–1.37)	Age, sex, cohort, smoking, type 2 diabetes	No associations were observed when results were stratified by Asian region (i.e. East Asia vs South Asia)

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Lin et al. (2013b) (cont.)			BMI				
			< 18.5	53	0.89 (0.64–1.24)		
			18.5–19.9	59	0.85 (0.63–1.15)		
			20–22.4	174	0.78 (0.63–0.96)		
			22.5–24.9	213	1.00		
			25–27.4	129	1.01 (0.81–1.27)		
			27.5–29.9	52	1.02 (0.74–1.39)		
			≥ 30	28	1.09 (0.72–1.65)		
			BMI				
			< 18.5	63	1.20 (0.90–1.61)		
			18.5–19.9	71	0.80 (0.61–1.05)		
			20–22.4	258	1.03 (0.86–1.24)		
			22.5–24.9	241	1.00		
			25–27.4	103	0.87 (0.69–1.10)		
			27.5–29.9	37	0.99 (0.69–1.42)		
			≥ 30	8	0.64 (0.30–1.35)		
Stolzenberg-Solomon et al. (2013)	501 698 Men and women Incidence	Pancreatic adenocarcinoma ICD-10: C25.0–25.9	BMI at age 18 yr			Smoking, total fat consumption, energy intake, sex	
NIH-AARP cohort USA 1995–2006			< 18.5	188	1.08 (0.92–1.27)		
			18.5–22.4	652	1.00		
			22.5–24.9	216	1.07 (0.92–1.25)		
			25–27.4	91	1.11 (0.89–1.39)		
			≥ 27.5	59	1.56 (1.19–2.03)		
			[<i>P</i> _{trend}]		[0.005]		
			BMI at age 35 yr				
			< 18.5	34	1.04 (0.73–1.48)		
			18.5–22.4	405	1.00		
			22.5–24.9	350	1.08 (0.94–1.25)		
			25–29.9	346	1.22 (1.05–1.41)		
			≥ 30	71	1.37 (1.06–1.79)		
			[<i>P</i> _{trend}]		[0.001]		

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Stolzenberg-Solomon et al. (2013) (cont.)			BMI at age 50 yr < 18.5 18.5–24.9 25–29.9 ≥ 30 [<i>P</i> _{trend}]	27 532 499 148	1.26 (0.85–1.85) 1.00 1.13 (1.00–1.29) 1.22 (1.02–1.47) [0.01]		
			BMI at age > 50 yr < 18.5 18.5–24.9 25–29.9 30–34.9 ≥ 35 [<i>P</i> _{trend}]	25 689 934 340 134	1.18 (0.79–1.75) 1.00 1.09 (0.98–1.20) 1.14 (1.00–1.30) 1.29 (1.07–1.55) [0.01]		
Bhaskaran et al. (2014) Clinical Practice Research Datalink United Kingdom 1987–2012	5 243 978 Men and women Incidence	Pancreas ICD-10: C25	BMI, per 5 kg/m ²	3851 total	1.05 (1.00–1.10)	Age, diabetes, smoking, alcohol consumption, SES, calendar year, sex	A 11% significant risk was observed when restricting to non-smokers only
Bethea et al. (2014) Pooled study of African Americans (7 cohorts) USA Follow-up times differ across cohorts (at least 5 yr)	239 597 Men and women Mortality NR Men Mortality	Pancreas ICD-10: C25 ICD-9: 157	BMI 18.5–24.9 25–29.9 30–34.9 ≥ 35 [<i>P</i> _{trend}] BMI 18.5–24.9 25–29.9 30–34.9 ≥ 35 [<i>P</i> _{trend}]	187 270 128 60 68 123 45 10	1.00 1.08 (0.90–1.31) 1.25 (0.99–1.57) 1.31 (0.97–1.77) [0.03] 1.00 1.15 (0.85–1.55) 1.36 (0.93–2.00) 1.14 (0.58–2.24) [0.20]	Age, smoking, education level, marital status, alcohol consumption, physical activity; analysis for men and women also adjusted for sex	

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Bethea et al. (2014) (cont.)	NR Women Mortality		BMI 18.5–24.9 25–29.9 30–34.9 ≥ 35 [<i>P</i> _{trend}]	119 147 83 50	1.00 1.03 (0.80–1.31) 1.16 (0.87–1.55) 1.34 (0.95–1.89) [0.08]		
Untawale et al. (2014) Singapore Chinese Health Study China 1993–2011	51 251 Men and women Incidence	Pancreas	BMI < 18.5 18.5–21.4 21.5–24.4 24.5–27.4 ≥ 27.5 [<i>P</i> _{trend}]	23 55 53 47 16	1.89 (1.15–3.09) 1.34 (0.92–1.96) 1.00 1.46 (0.99–2.17) 1.02 (0.58–1.79) [0.08]	Age, sex, enrolment year, dialect, education level, diabetes, smoking history, alcohol consumption, diet, physical activity, sleep duration, energy intake	
Genkinger et al. (2015) National Cancer Institute BMI and Mortality Cohort Consortium (pooled analysis of 20 cohort studies) Follow-up varies by cohort	1 564 218 for BMI at baseline 1 096 492 for BMI in early adulthood 647 478 for WC Men and women Mortality	Pancreas ICD-9: 157 ICD-10: C25	BMI at baseline 15–18.4 18.5–21 21–22.9 23–24.9 25–27.4 27.5–29.9 30–34.9 35– < 60 continuous	51 296 574 908 1134 653 617 212	1.10 (0.83–1.47) 1.01 (0.87–1.16) 1.00 1.12 (1.01–1.24) 1.14 (1.03–1.26) 1.14 (1.01–1.27) 1.27 (1.13–1.43) 1.34 (1.14–1.57) 1.09 (1.05–1.12)	Age, race, education level, marital status, alcohol consumption, physical activity, smoking status	The positive association of WC with increased risk of pancreatic cancer mortality remained significant when additionally adjusting for BMI No differences between men and women in associations with BMI at baseline and in early adulthood, or with WC Stronger positive associations of pancreatic cancer risk with BMI change in women than in men

Table 2.2.7a (continued)

Reference Cohort Location Follow-up period	Total number of subjects Sex Incidence/mortality	Organ site or cancer type (ICD code)	Exposure categories	Exposed cases	Relative risk (95% CI)	Covariates	Comments
Genkinger et al. (2015) (cont.)			BMI in early adulthood				
			15–18.4	376	1.01 (0.89–1.14)		
			18.5–21	1036	0.98 (0.89–1.08)		
			21–22.9	814	1.00		
			23–24.9	510	1.13 (1.01–1.26)		
			25–27.4	331	1.36 (1.20–1.55)		
			27.5–29.9	93	1.48 (1.20–1.84)		
			30–39.9	61	1.43 (1.11–1.85)		
			per 5 kg/m ²		1.18 (1.11–1.25)		
			BMI change				
			< –2.5	117	1.24 (1.01–1.53)		
			–2.5 to 0	269	1.12 (0.97–1.29)		
			0–2.4	658	1.00		
			2.5–4.9	828	1.07 (0.97–1.19)		
			5–7.4	640	1.11 (0.99–1.24)		
			7.5–9.9	357	1.11 (0.98–1.27)		
			≥ 10	354	1.28 (1.12–1.47)		
			per 5 kg/m ²		1.05 (1.01–1.10)		
			WC (cm), quartiles (sex-specific)				
			Men: Women:				
			< 90 < 70	385	1.00		
			90–99 70–79	660	1.11 (0.98–1.27)		
			110–109 80–89	531	1.26 (1.10–1.45)		
			≥ 110 ≥ 90	371	1.31 (1.12–1.54)		
			per 10 cm		1.09 (1.04–1.13)		
			[P _{trend}]		[< 0.0001]		
Meyer et al. (2015) Swiss cohort study Switzerland 1977–2008	35 703 Men and women Mortality	Pancreas ICD-8: 157 ICD-10: C25	BMI < 25 25–29.9 ≥ 30	127 total	1.00 1.20 (0.81–1.78) 1.60 (0.93–2.75)	Sex, age, survey, alcohol consumption, physical activity, civil status, years of education, nationality, diet	

ATBC, Alpha-Tocopherol, Beta-Carotene Cancer Prevention Study; BMI, body mass index (in kg/m²); BP, blood pressure; CI, confidence interval; EPIC, European Prospective Investigation into Cancer and Nutrition; ICD, International Classification of Diseases; JACC, Japan Collaborative Cohort Study for Evaluation of Cancer Risk; NIH-AARP, National Institutes of Health–AARP Diet and Health Study; NR, not reported; SE, standard error; SES, socioeconomic status; WC, waist circumference; yr, year or years

Table 2.2.7b Case-control studies of measures of body fatness and cancer of the pancreas

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments
Bueno de Mesquita et al. (1990) The Netherlands 1984–1988	Men: 89 Women: 79 Population	BMI 2 yr before diagnosis < 23 > 27.9 [<i>P</i> _{trend}]	Men: 20 20	1.00 0.88 (0.40–1.90) [> 0.50]	10-yr age group, response status, total smoking	
Ghadirian et al. (1991) Canada 1984–1988	179 Population	BMI < 21.1 > 26.5	Women: 15 12	1.00 1.10 (0.46–2.80) [> 0.90]	Age, sex, response status, cigarette smoking	
Ji et al. (1996) China 1990–1993	Men: 255 Women: 183 Population	BMI < 19.4 > 22.5 [<i>P</i> _{trend}]	Men: 72 59	1.0 1.40 (0.91–2.10) [0.14]	Age, income, smoking, physical activity, response status, diabetes, vitamin C, total energy In women only: green tea drinking	
Hanley et al. (2001) Canada (7 Canadian provinces) 1994–1997	312 Population	BMI 2 yr before interview < 23.7 23.7– < 25.8 25.8– < 28.3 ≥ 28.3 [<i>P</i> _{trend}]	Men: 31 44 40 57	1.0 1.79 (1.01–3.19) 1.36 (0.74–2.49) 1.90 (1.08–3.35) [0.03]	Age, province, percentage weight change, energy intake, composite index of physical activity	Men who reported a 2.9% or greater decrease in weight from their maximum lifetime weight were at significantly reduced risk of pancreatic cancer
		BMI 2 yr before interview < 22.1 22.1– < 24.5 24.5– < 27.4 ≥ 27.4 [<i>P</i> _{trend}]	Women: 32 22 34 51	1.0 0.64 (0.35–1.18) 0.78 (0.44–1.40) 1.21 (0.70–2.06) [0.39]	Age, province, energy intake, age at first menstruation, cigarette smoking	Women who reported a 12.5% or greater decrease in weight from their maximum lifetime weight were at significantly reduced risk of pancreatic cancer

Table 2.2.7b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments
Silverman (2001) USA (Atlanta, Detroit, New Jersey) 1986–1989	Men: 218 Women: 213 Population	BMI 17.35–23.13 23.17–25.07 25.09–27.18 ≥ 27.2 [<i>P</i> _{trend}] BMI 20.49–27.54 27.56–30.25 30.30–34.21 ≥ 34.43 [<i>P</i> _{trend}]	Men: 51 39 55 73 Women: 40 54 57 62	1.0 0.8 (0.5–1.3) 1.1 (0.7–1.7) 1.5 (1.0–2.3) [0.019] 1.0 1.4 (0.9–2.3) 1.5 (0.9–2.4) 1.5 (0.9–2.5) [0.129]	Age at diagnosis/interview, race, area, diabetes mellitus, gall bladder disease, cigarette smoking, alcohol consumption, income (men), marital status (women), energy intake from food	An interaction was observed between BMI and total energy intake in relation to pancreatic cancer risk; those with high BMI and high energy intake were at 60% increased risk.
Eberle et al. (2005) USA 1995–1999	Men: 291 Women: 241 Population	Adult BMI < 23.1 23.1– < 25.1 25.1– < 27.1 ≥ 27.1 [<i>P</i> _{trend}] Adult BMI < 21.5 21.5– < 23.4 23.4– < 25.8 ≥ 25.8 [<i>P</i> _{trend}] BMI at age 25 yr < 20.9 20.9– < 22.8 22.8– < 24.7 ≥ 24.7 [<i>P</i> _{trend}] BMI at age 25 yr < 19.7 19.7– < 21.0 21.0– < 22.5 ≥ 22.5 [<i>P</i> _{trend}]	Men: 48 70 75 95 Women: 67 51 62 61 Men: 44 76 79 91 Women: 54 50 64 72	1.0 1.6 (1.04–2.5) 1.6 (1.1–2.5) 2.1 (1.4–3.2) [0.0007] 1.0 0.72 (0.47–1.1) 0.86 (0.58–1.3) 0.91 (0.61–1.4) [NS] 1.0 1.7 (1.1–2.6) 1.8 (1.2–2.8) 2.0 (1.4–3.1) [0.001] 1.0 0.88 (0.57–1.4) 1.2 (0.77–1.7) 1.3 (0.84–1.9) [0.13]	Age, cigarette smoking only for usual BMI in men	

Table 2.2.7b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments
Fryzek et al. (2005) USA (South- eastern Michigan) 1996–1999	Men: 119 Women: 112 Population	Current BMI, quartiles				Age, sex, race, county group, smoking, relative with pancreatic cancer, income, medical history of diabetes
		Q1: ≤ 24.4	33	1.0		
		Q2: 24.5–27.3	59	0.4 (0.3–0.7)		
		Q3: 27.4–31.5	22	0.2 (0.1–0.3)		
		Q4: 31.5–67.8	17	0.1 (0.0–0.2)		
		[<i>P</i> _{trend}]		< 0.0001]		
		BMI 5 yr before interview, quartiles				
		Q1: ≤ 24.1	46	1.0		
		Q2: 24.2–26.5	56	1.1 (0.6–1.8)		
		Q3: 26.6–30.3	68	1.3 (0.8–2.2)		
		Q4: 30.4–68.5	61	1.0 (0.6–1.8)		
		[<i>P</i> _{trend}]		[0.77]		
		BMI 20 yr before interview, quartiles				
			All:			
		Q1: 0.0–22.2	43	1.0		
		Q2: 22.3–24.4	48	1.1 (0.6–1.9)		
		Q3: 24.5–27.4	71	1.6 (0.9–2.6)		
Q4: 27.5–43.0	69	1.4 (0.8–2.5)				
[<i>P</i> _{trend}]		[0.15]				
	Men:					
Q1: 0.0–22.2	8	1.0				
Q2: 22.3–24.4	25	1.6 (0.6–4.1)				
Q3: 24.5–27.4	43	2.6 (1.0–6.4)				
Q4: 27.5–43.0	43	2.4 (1.0–6.2)				
[<i>P</i> _{trend}]		[0.048]				
	Women:					
Q1: 0.0–22.2	35	1.0				
Q2: 22.3–24.4	23	1.2 (0.6–2.5)				
Q3: 24.5–27.4	28	1.5 (0.7–3.0)				
Q4: 27.5–43.0	26	1.4 (0.7–3.0)				
[<i>P</i> _{trend}]		[0.37]				

Table 2.2.7b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments
Fryzek et al. (2005) (cont.)		BMI, ever-smokers				
		≤ 22.2	34	1.0		
		22.3–24.4	32	1.0 (0.5–1.8)		
		24.5–27.4	52	1.7 (0.9–3.1)		
		27.5–43.0	36	0.9 (0.5–1.8)		
		[<i>P</i> _{trend}]		[0.94]		
		BMI, never-smokers				
		≤ 22.2	9	1.0		
		22.3–24.4	16	1.6 (0.6–0.46)		
		24.5–27.4	19	1.5 (0.5–4.0)		
		27.5–43.0	33	3.3 (1.2–9.2)		
		[<i>P</i> _{trend}]		[0.014]		
Pezzilli et al. (2005) Italy	400 Hospital	BMI before diagnosis				Matched for sex, age (± 5 yr), social class, geographical region
		< 23	110	1.01 (0.72–1.41)		
		23–29.9	246	1.00		
		≥ 30	44	0.96 (0.60–1.53)		
Lo et al. (2007) Egypt 2001–2004	194 Hospital	BMI 1 yr before				Age, sex, residence
		< 27	99	1.0		
		27–31	59	1.4 (0.9–2.2)		
		≥ 32	28	1.5 (0.8–2.9)		
Anderson et al. (2009) Canada (Ontario) 2003–2007	422 Population	BMI 1 yr before				Age, education level, smoking status, family history of pancreatic cancer, weekly fruit servings, alcohol consumption, caffeinated beverages, allergies
		< 25	148	1.00		
		25–29.9	183	1.77 (1.19–2.62)		
		≥ 30	83	3.51 (1.92–6.39)		

Table 2.2.7b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments
Li et al. (2009) USA (Texas) 2004–2008	841 (men: 496; women: 282) Population (proxy controls)	Mean lifetime BMI, per 5 kg/m ² increase	All: 841 Men: 496 Women: 345	1.55 (1.32–1.84) 1.80 (1.45–2.23) 1.32 (1.02–1.70)	Age, race, sex, smoking, alcohol consumption, history of diabetes, family history of cancer	Associations were somewhat stronger in ever-smokers than in never-smokers (1.75 vs 1.46) When stratifying BMI by age ranges, the greatest risk of pancreatic cancer was found at the ages of onset of overweight and/or obesity between 14–19 yr and 20–29 yr
Urayama et al. (2011) Czech Republic and Slovakia 2004–2009	574 Population	BMI at age 20 yr 18.5–21.1 21.2–22.8 22.9–24.5 > 24.5 per 5 kg/m ² BMI at age 40 yr 18.5–23.0 23.1–24.8 24.9–27.3 > 27.3 per 5 kg/m ² BMI 2 yr before interview 18.5–24.3 24.4–27.1 27.2–30.4 > 30.4 per 5 kg/m ²	101 113 161 164 106 114 154 173 131 151 153 130	1.00 1.15 (0.79–1.69) 1.81 (1.24–2.63) 1.79 (1.23–2.61) 1.45 (1.15–1.84) 1.00 1.04 (0.72–1.52) 1.40 (0.97–2.03) 1.57 (1.09–2.27) 1.24 (1.04–1.47) 1.00 1.07 (0.75–1.52) 1.04 (0.73–1.47) 0.91 (0.63–1.30) 0.98 (0.85–1.13)	Centre, age at interview, sex, diabetes mellitus, chronic pancreatitis, smoking, alcohol consumption	
Lin et al. (2013a) Japan 2010–2012	360 (men: 145; women: 215) Hospital	BMI in the yr before study entry < 25 25.0–29.9 ≥ 30	278 64 16	1.00 0.96 (0.65–1.43) 1.21 (0.53–2.77)	Age, sex, history of diabetes, cigarette smoking	

Table 2.2.7b (continued)

Reference Study location Period	Total number of cases Source of controls	Exposure categories	Exposed cases	Relative risk (95% CI)	Adjustment for confounding	Comments
Zheng et al. (2016) China 2011–2013	323 Population (family members of other inpatients)	Current BMI < 24.0 ≥ 24.0	197 126	1.00 1.77 (1.22–2.57)	Age, sex, race, residential areas, smoking, tea drinking, mental pressure, family history of pancreatic cancer, diabetes, gallstone, intake of pickles and vegetables	
<i>Pancreatic neuroendocrine tumours</i>						
Halfdanarson et al. (2014) USA (Mayo Clinic Rochester 2004–2011)	309 Hospital	Current BMI < 30 ≥ 30	141 61	1.00 1.65 (1.11–2.45)		

BMI, body mass index (in kg/m²); CI, confidence interval; NS, not significant; yr, year or years

Table 2.2.7c Meta-analyses of measures of body fatness and cancer of the pancreas

Reference	Total number of studies Total number of cases	Exposure categories	Relative risk (95% CI)	Adjustment for confounding	Comments
Michaud et al. (2001)	2 cohort studies 350	BMI < 23 23–24.9 25.0–26.9 27.0–39.9 ≥ 30 [<i>P</i> _{trend}]	1.00 1.09 (0.79–1.49) 1.29 (0.92–1.80) 1.30 (0.91–1.87) 1.72 (1.19–2.48) [0.003]	Height, BMI at baseline, age, smoking, history of diabetes mellitus, cholecystectomy	
Berrington de Gonzalez et al. (2003)	6 case-control studies 8 cohort studies 6391	BMI, per 1 kg/m ² increase	1.02 (1.01–1.03)	Age (all), smoking and diabetes (not all studies)	No differences were observed between men and women or when stratifying by study design (cohort vs case-control)
Larsson et al. (2007)	21 prospective studies (13 in men and 10 in women) 8062	BMI, per 5 kg/m ² increase	All: 1.12 (1.06–1.17) Men: 1.16 (1.05–1.28) Women: 1.10 (1.02–1.19)	All studies adjusted for age, cigarette smoking; 13 studies also adjusted for diabetes	
Renehan et al. (2008)	12 prospective studies All studies: Men: 2390 Women: 2053 Studies with both sexes: Men: 839 Women: 778	BMI, per 5 kg/m ² increase	Men: 1.07 (0.93–1.23) Women: 1.12 (1.03–1.23) Men: 1.07 (0.83–1.39) Women: 1.12 (0.95–1.33)	Method of BMI determination, extent of cancer site-specific risk factor adjustment, geographical region	When stratifying by region, the highest risk ratios were reported in North America (<i>n</i> = 2 studies)
Guh et al. (2009)	10 prospective studies (4 in men and 6 in women) NR	BMI Normal Overweight Obesity BMI Normal Overweight Obesity	Men: 1.00 1.28 (0.94–1.75) 2.29 (1.65–3.19) Women: 1.00 1.24 (0.98–1.56) 1.60 (1.17–2.20)		

Table 2.2.7c (continued)

Reference	Total number of studies Total number of cases	Exposure categories	Relative risk (95% CI)	Adjustment for confounding	Comments
Aune et al. (2012)	23 prospective studies 9504	BMI, per 5 kg/m ² increase	All (23 studies): 1.10 (1.07–1.14) Men (14 studies): 1.13 (1.04–1.22) Women (15 studies): 1.10 (1.04–1.16) Never-smoker (5 studies): 1.11 (1.04–1.17) Ever-smoker (4 studies): 1.03 (0.95–1.10)		Non-linear association between BMI and pancreatic cancer risk, with the most pronounced increase in risk in those with BMI > 35
WCRF/AICR (2012)	23 cohort studies 9504	BMI, per 5 kg/m ² increase	Incidence: 1.10 (1.07–1.14)	NR	No differences were observed between men and women. Some evidence for a non-linear dose-response with an increase in risk from BMI ≥ 25
	5 cohort studies 949	BMI, per 5 kg/m ² increase	Mortality: 1.10 (1.02–1.19)		
	4 cohort studies 900	WC, per 10 cm increase	1.11 (1.05–1.18)	NR	
	4 cohort studies 900	BMI at age 20 yr, per 5 kg/m ² increase	1.12 (0.97–1.29)	NR	

BMI, body mass index (in kg/m²); CI, confidence interval; NR, not reported; WC, waist circumference; WCRF/AICR, World Cancer Research Fund/American Institute for Cancer Research; yr, year or years

References

- Anderson LN, Cotterchio M, Gallinger S (2009). Lifestyle, dietary, and medical history factors associated with pancreatic cancer risk in Ontario, Canada. *Cancer Causes Control*, 20(6):825–34. doi:[10.1007/s10552-009-9303-5](https://doi.org/10.1007/s10552-009-9303-5) PMID:[19194662](https://pubmed.ncbi.nlm.nih.gov/19194662/)
- Arnold LD, Patel AV, Yan Y, Jacobs EJ, Thun MJ, Calle EE, et al. (2009). Are racial disparities in pancreatic cancer explained by smoking and overweight/obesity? *Cancer Epidemiol Biomarkers Prev*, 18(9):2397–405. doi:[10.1158/1055-9965.EPI-09-0080](https://doi.org/10.1158/1055-9965.EPI-09-0080) PMID:[19723915](https://pubmed.ncbi.nlm.nih.gov/19723915/)
- Arslan AA, Helzlsouer KJ, Kooperberg C, Shu XO, Steplowski E, Bueno-de-Mesquita HB, et al.; Pancreatic Cancer Cohort Consortium (PanScan) (2010). Anthropometric measures, body mass index, and pancreatic cancer: a pooled analysis from the Pancreatic Cancer Cohort Consortium (PanScan). *Arch Intern Med*, 170(9):791–802. doi:[10.1001/archinternmed.2010.63](https://doi.org/10.1001/archinternmed.2010.63) PMID:[20458087](https://pubmed.ncbi.nlm.nih.gov/20458087/)
- Aune D, Greenwood DC, Chan DS, Vieira R, Vieira AR, Navarro Rosenblatt DA, et al. (2012). Body mass index, abdominal fatness and pancreatic cancer risk: a systematic review and non-linear dose-response meta-analysis of prospective studies. *Ann Oncol*, 23(4):843–52. doi:[10.1093/annonc/mdr398](https://doi.org/10.1093/annonc/mdr398) PMID:[21890910](https://pubmed.ncbi.nlm.nih.gov/21890910/)
- Batty GD, Shipley MJ, Jarrett RJ, Breeze E, Marmot MG, Smith GD (2005). Obesity and overweight in relation to organ-specific cancer mortality in London (UK): findings from the original Whitehall study. *Int J Obes (Lond)*, 29(10):1267–74. doi:[10.1038/sj.ijo.0803020](https://doi.org/10.1038/sj.ijo.0803020) PMID:[15997248](https://pubmed.ncbi.nlm.nih.gov/15997248/)
- Berrington de González A, Spencer EA, Bueno-de-Mesquita HB, Roddam A, Stolzenberg-Solomon R, Halkjaer J, et al. (2006). Anthropometry, physical activity, and the risk of pancreatic cancer in the European Prospective Investigation into Cancer and Nutrition. *Cancer Epidemiol Biomarkers Prev*, 15(5):879–85. doi:[10.1158/1055-9965.EPI-05-0800](https://doi.org/10.1158/1055-9965.EPI-05-0800) PMID:[16702364](https://pubmed.ncbi.nlm.nih.gov/16702364/)
- Berrington de Gonzalez A, Sweetland S, Spencer E (2003). A meta-analysis of obesity and the risk of pancreatic cancer. *Br J Cancer*, 89(3):519–23. doi:[10.1038/sj.bjc.6601140](https://doi.org/10.1038/sj.bjc.6601140) PMID:[12888824](https://pubmed.ncbi.nlm.nih.gov/12888824/)
- Bethea TN, Kitahara CM, Sonderman J, Patel AV, Harvey C, Knutsen SF, et al. (2014). A pooled analysis of body mass index and pancreatic cancer mortality in African Americans. *Cancer Epidemiol Biomarkers Prev*, 23(10):2119–25. doi:[10.1158/1055-9965.EPI-14-0422](https://doi.org/10.1158/1055-9965.EPI-14-0422) PMID:[25017247](https://pubmed.ncbi.nlm.nih.gov/25017247/)
- Bhaskaran K, Douglas I, Forbes H, dos-Santos-Silva I, Leon DA, Smeeth L (2014). Body-mass index and risk of 22 specific cancers: a population-based cohort study of 5.24 million UK adults. *Lancet*, 384(9945):755–65. doi:[10.1016/S0140-6736\(14\)60892-8](https://doi.org/10.1016/S0140-6736(14)60892-8) PMID:[25129328](https://pubmed.ncbi.nlm.nih.gov/25129328/)
- Bosetti C, Bertuccio P, Malvezzi M, Levi F, Chatenoud L, Negri E, et al. (2013). Cancer mortality in Europe, 2005–2009, and an overview of trends since 1980. *Ann Oncol*, 24(10):2657–71. doi:[10.1093/annonc/mdt301](https://doi.org/10.1093/annonc/mdt301) PMID:[23921790](https://pubmed.ncbi.nlm.nih.gov/23921790/)
- Bueno de Mesquita HB, Moerman CJ, Runia S, Maisonneuve P (1990). Are energy and energy-providing nutrients related to exocrine carcinoma of the pancreas? *Int J Cancer*, 46(3):435–44. doi:[10.1002/ijc.2910460319](https://doi.org/10.1002/ijc.2910460319) PMID:[2394510](https://pubmed.ncbi.nlm.nih.gov/2394510/)
- Eberle CA, Bracci PM, Holly EA (2005). Anthropometric factors and pancreatic cancer in a population-based case-control study in the San Francisco Bay area. *Cancer Causes Control*, 16(10):1235–44. doi:[10.1007/s10552-005-0354-y](https://doi.org/10.1007/s10552-005-0354-y) PMID:[16215874](https://pubmed.ncbi.nlm.nih.gov/16215874/)
- Ferlay J, Soerjomataram I, Dikshit R, Eser S, Mathers C, Rebelo M, et al. (2015). Cancer incidence and mortality worldwide: sources, methods and major patterns in GLOBOCAN 2012. *Int J Cancer*, 136(5):E359–86. doi:[10.1002/ijc.29210](https://doi.org/10.1002/ijc.29210) PMID:[25220842](https://pubmed.ncbi.nlm.nih.gov/25220842/)
- Friedman GD, van den Eeden SK (1993). Risk factors for pancreatic cancer: an exploratory study. *Int J Epidemiol*, 22(1):30–7. doi:[10.1093/ije/22.1.30](https://doi.org/10.1093/ije/22.1.30) PMID:[8449644](https://pubmed.ncbi.nlm.nih.gov/8449644/)
- Fryzek JP, Schenk M, Kinnard M, Greenson JK, Garabrant DH (2005). The association of body mass index and pancreatic cancer in residents of southeastern Michigan, 1996–1999. *Am J Epidemiol*, 162(3):222–8. doi:[10.1093/aje/kwi183](https://doi.org/10.1093/aje/kwi183) PMID:[15987732](https://pubmed.ncbi.nlm.nih.gov/15987732/)
- Gapstur SM, Gann PH, Lowe W, Liu K, Colangelo L, Dyer A (2000). Abnormal glucose metabolism and pancreatic cancer mortality. *JAMA*, 283(19):2552–8. doi:[10.1001/jama.283.19.2552](https://doi.org/10.1001/jama.283.19.2552) PMID:[10815119](https://pubmed.ncbi.nlm.nih.gov/10815119/)
- Genkinger JM, Kitahara CM, Bernstein L, Berrington de Gonzalez A, Brotzman M, Elena JW, et al. (2015). Central adiposity, obesity during early adulthood, and pancreatic cancer mortality in a pooled analysis of cohort studies. *Ann Oncol*, 26(11):2257–66. doi:[10.1093/annonc/mdv355](https://doi.org/10.1093/annonc/mdv355) PMID:[26347100](https://pubmed.ncbi.nlm.nih.gov/26347100/)
- Genkinger JM, Spiegelman D, Anderson KE, Bernstein L, van den Brandt PA, Calle EE, et al. (2011). A pooled analysis of 14 cohort studies of anthropometric factors and pancreatic cancer risk. *Int J Cancer*, 129(7):1708–17. doi:[10.1002/ijc.25794](https://doi.org/10.1002/ijc.25794) PMID:[21105029](https://pubmed.ncbi.nlm.nih.gov/21105029/)
- Ghadirian P, Simard A, Baillargeon J, Maisonneuve P, Boyle P (1991). Nutritional factors and pancreatic cancer in the francophone community in Montréal, Canada. *Int J Cancer*, 47(1):1–6. doi:[10.1002/ijc.2910470102](https://doi.org/10.1002/ijc.2910470102) PMID:[1845960](https://pubmed.ncbi.nlm.nih.gov/1845960/)
- Guh DP, Zhang W, Bansback N, Amarsi Z, Birmingham CL, Anis AH (2009). The incidence of co-morbidities related to obesity and overweight: a systematic review and meta-analysis. *BMC Public Health*, 9(1):88. doi:[10.1186/1471-2458-9-88](https://doi.org/10.1186/1471-2458-9-88) PMID:[19320986](https://pubmed.ncbi.nlm.nih.gov/19320986/)
- Halfdanarson TR, Bamlet WR, McWilliams RR, Hobday TJ, Burch PA, Rabe KG, et al. (2014). Risk factors for pancreatic neuroendocrine tumors: a clinic-based

- case-control study. *Pancreas*, 43(8):1219–22. doi:[10.1097/MPA.0000000000000234](https://doi.org/10.1097/MPA.0000000000000234) PMID:[25291526](https://pubmed.ncbi.nlm.nih.gov/25291526/)
- Hanley AJ, Johnson KC, Villeneuve PJ, Mao Y; Canadian Cancer Registries Epidemiology Research Group (2001). Physical activity, anthropometric factors and risk of pancreatic cancer: results from the Canadian enhanced cancer surveillance system. *Int J Cancer*, 94(1):140–7. doi:[10.1002/ijc.1446](https://doi.org/10.1002/ijc.1446) PMID:[11668489](https://pubmed.ncbi.nlm.nih.gov/11668489/)
- IARC (2002). Weight control and physical activity. Lyon, France: IARC Press (IARC Handbooks of Cancer Prevention, Vol. 6). Available from: <http://publications.iarc.fr/376>.
- Isaksson B, Jonsson F, Pedersen NL, Larsson J, Feychting M, Permert J (2002). Lifestyle factors and pancreatic cancer risk: a cohort study from the Swedish Twin Registry. *Int J Cancer*, 98(3):480–2. doi:[10.1002/ijc.10256](https://doi.org/10.1002/ijc.10256) PMID:[11920604](https://pubmed.ncbi.nlm.nih.gov/11920604/)
- Jee SH, Yun JE, Park EJ, Cho ER, Park IS, Sull JW, et al. (2008). Body mass index and cancer risk in Korean men and women. *Int J Cancer*, 123(8):1892–6. doi:[10.1002/ijc.23719](https://doi.org/10.1002/ijc.23719) PMID:[18651571](https://pubmed.ncbi.nlm.nih.gov/18651571/)
- Ji BT, Hatch MC, Chow WH, McLaughlin JK, Dai Q, Howe GR, et al. (1996). Anthropometric and reproductive factors and the risk of pancreatic cancer: a case-control study in Shanghai, China. *Int J Cancer*, 66(4):432–7. doi:[10.1002/\(SICI\)1097-0215\(19960516\)66:4<432::AID-IJC4>3.0.CO;2-X](https://doi.org/10.1002/(SICI)1097-0215(19960516)66:4<432::AID-IJC4>3.0.CO;2-X) PMID:[8635856](https://pubmed.ncbi.nlm.nih.gov/8635856/)
- Jiao L, Berrington de Gonzalez A, Hartge P, Pfeiffer RM, Park Y, Freedman DM, et al. (2010). Body mass index, effect modifiers, and risk of pancreatic cancer: a pooled study of seven prospective cohorts. *Cancer Causes Control*, 21(8):1305–14. doi:[10.1007/s10552-010-9558-x](https://doi.org/10.1007/s10552-010-9558-x) PMID:[20383573](https://pubmed.ncbi.nlm.nih.gov/20383573/)
- Johansen D, Borgström A, Lindkvist B, Manjer J (2009). Different markers of alcohol consumption, smoking and body mass index in relation to risk of pancreatic cancer. A prospective cohort study within the Malmö Preventive Project. *Pancreatology*, 9(5):677–86. doi:[10.1159/000212088](https://doi.org/10.1159/000212088) PMID:[19684432](https://pubmed.ncbi.nlm.nih.gov/19684432/)
- Klein AP, Lindström S, Mendelsohn JB, Steplowski E, Arslan AA, Bueno-de-Mesquita HB, et al. (2013). An absolute risk model to identify individuals at elevated risk for pancreatic cancer in the general population. *PLoS One*, 8(9):e72311. doi:[10.1371/journal.pone.0072311](https://doi.org/10.1371/journal.pone.0072311) PMID:[24058443](https://pubmed.ncbi.nlm.nih.gov/24058443/)
- Kohler BA, Sherman RL, Howlader N, Jemal A, Ryerson AB, Henry KA, et al. (2015). Annual Report to the Nation on the Status of Cancer, 1975–2011, featuring incidence of breast cancer subtypes by race/ethnicity, poverty, and state. *J Natl Cancer Inst*, 107(6):djv048. doi:[10.1093/jnci/djv048](https://doi.org/10.1093/jnci/djv048) PMID:[25825511](https://pubmed.ncbi.nlm.nih.gov/25825511/)
- Larsson SC, Orsini N, Wolk A (2007). Body mass index and pancreatic cancer risk: a meta-analysis of prospective studies. *Int J Cancer*, 120(9):1993–8. doi:[10.1002/ijc.22535](https://doi.org/10.1002/ijc.22535) PMID:[17266034](https://pubmed.ncbi.nlm.nih.gov/17266034/)
- Larsson SC, Permert J, Håkansson N, Näslund I, Bergkvist L, Wolk A (2005). Overall obesity, abdominal adiposity, diabetes and cigarette smoking in relation to the risk of pancreatic cancer in two Swedish population-based cohorts. *Br J Cancer*, 93(11):1310–5. doi:[10.1038/sj.bjc.6602868](https://doi.org/10.1038/sj.bjc.6602868) PMID:[16288300](https://pubmed.ncbi.nlm.nih.gov/16288300/)
- Li D, Morris JS, Liu J, Hassan MM, Day RS, Bondy ML, et al. (2009). Body mass index and risk, age of onset, and survival in patients with pancreatic cancer. *JAMA*, 301(24):2553–62. doi:[10.1001/jama.2009.886](https://doi.org/10.1001/jama.2009.886) PMID:[19549972](https://pubmed.ncbi.nlm.nih.gov/19549972/)
- Lin Y, Fu R, Grant E, Chen Y, Lee JE, Gupta PC, et al. (2013b). Association of body mass index and risk of death from pancreas cancer in Asians: findings from the Asia Cohort Consortium. *Eur J Cancer Prev*, 22(3):244–50.
- Lin Y, Kikuchi S, Tamakoshi A, Yagyu K, Obata Y, Inaba Y, et al.; JACC Study Group (2007). Obesity, physical activity and the risk of pancreatic cancer in a large Japanese cohort. *Int J Cancer*, 120(12):2665–71. doi:[10.1002/ijc.22614](https://doi.org/10.1002/ijc.22614) PMID:[17304505](https://pubmed.ncbi.nlm.nih.gov/17304505/)
- Lin Y, Ueda J, Yagyu K, Ishii H, Ueno M, Egawa N, et al. (2013a). Association between variations in the fat mass and obesity-associated gene and pancreatic cancer risk: a case-control study in Japan. *BMC Cancer*, 13(1):337. doi:[10.1186/1471-2407-13-337](https://doi.org/10.1186/1471-2407-13-337) PMID:[23835106](https://pubmed.ncbi.nlm.nih.gov/23835106/)
- Lo AC, Soliman AS, El-Ghawalby N, Abdel-Wahab M, Fathy O, Khaled HM, et al. (2007). Lifestyle, occupational, and reproductive factors in relation to pancreatic cancer risk. *Pancreas*, 35(2):120–9. doi:[10.1097/mpa.0b013e318053e7d3](https://doi.org/10.1097/mpa.0b013e318053e7d3) PMID:[17632317](https://pubmed.ncbi.nlm.nih.gov/17632317/)
- Luo J, Iwasaki M, Inoue M, Sasazuki S, Otani T, Ye W, et al.; JPHC Study Group (2007). Body mass index, physical activity and the risk of pancreatic cancer in relation to smoking status and history of diabetes: a large-scale population-based cohort study in Japan – the JPHC study. *Cancer Causes Control*, 18(6):603–12. doi:[10.1007/s10552-007-9002-z](https://doi.org/10.1007/s10552-007-9002-z) PMID:[17401636](https://pubmed.ncbi.nlm.nih.gov/17401636/)
- Luo J, Margolis KL, Adami HO, LaCroix A, Ye W; Women's Health Initiative Investigators (2008). Obesity and risk of pancreatic cancer among postmenopausal women: the Women's Health Initiative (United States). *Br J Cancer*, 99(3):527–31. doi:[10.1038/sj.bjc.6604487](https://doi.org/10.1038/sj.bjc.6604487) PMID:[18628761](https://pubmed.ncbi.nlm.nih.gov/18628761/)
- Ma J, Jemal A (2013). The rise and fall of cancer mortality in the USA: why does pancreatic cancer not follow the trend? *Future Oncol*, 9(7):917–9. doi:[10.2217/fon.13.76](https://doi.org/10.2217/fon.13.76) PMID:[23837751](https://pubmed.ncbi.nlm.nih.gov/23837751/)
- Máchová L, Cízek L, Horáková D, Koutná J, Lorenc J, Janoutová G, et al. (2007). Association between obesity and cancer incidence in the population of the District Sumperk, Czech Republic. *Onkologie*, 30(11):538–42. doi:[10.1159/000108284](https://doi.org/10.1159/000108284) PMID:[17992023](https://pubmed.ncbi.nlm.nih.gov/17992023/)
- Meinhold CL, Berrington de Gonzalez A, Albanes D, Weinstein SJ, Taylor PR, Virtamo J, et al. (2009). Predictors of fasting serum insulin and glucose and

- the risk of pancreatic cancer in smokers. *Cancer Causes Control*, 20(5):681–90. doi:[10.1007/s10552-008-9281-z](https://doi.org/10.1007/s10552-008-9281-z) PMID:[19083105](https://pubmed.ncbi.nlm.nih.gov/19083105/)
- Meyer J, Rohrmann S, Bopp M, Faeh D; Swiss National Cohort Study Group (2015). Impact of smoking and excess body weight on overall and site-specific cancer mortality risk. *Cancer Epidemiol Biomarkers Prev*, 24(10):1516–22. doi:[10.1158/1055-9965.EPI-15-0415](https://doi.org/10.1158/1055-9965.EPI-15-0415) PMID:[26215293](https://pubmed.ncbi.nlm.nih.gov/26215293/)
- Michaud DS, Giovannucci E, Willett WC, Colditz GA, Stampfer MJ, Fuchs CS (2001). Physical activity, obesity, height, and the risk of pancreatic cancer. *JAMA*, 286(8):921–9. doi:[10.1001/jama.286.8.921](https://doi.org/10.1001/jama.286.8.921) PMID:[11509056](https://pubmed.ncbi.nlm.nih.gov/11509056/)
- Nöthlings U, Wilkens LR, Murphy SP, Hankin JH, Henderson BE, Kolonel LN (2007). Body mass index and physical activity as risk factors for pancreatic cancer: the Multiethnic Cohort Study. *Cancer Causes Control*, 18(2):165–75. doi:[10.1007/s10552-006-0100-0](https://doi.org/10.1007/s10552-006-0100-0) PMID:[17219012](https://pubmed.ncbi.nlm.nih.gov/17219012/)
- Parr CL, Batty GD, Lam TH, Barzi F, Fang X, Ho SC et al.; Asia-Pacific Cohort Studies Collaboration (2010). Body-mass index and cancer mortality in the Asia-Pacific Cohort Studies Collaboration: pooled analyses of 424,519 participants. *Lancet Oncol*, 11(8):741–52. doi:[10.1016/S1470-2045\(10\)70141-8](https://doi.org/10.1016/S1470-2045(10)70141-8) PMID:[20594911](https://pubmed.ncbi.nlm.nih.gov/20594911/)
- Patel AV, Rodriguez C, Bernstein L, Chao A, Thun MJ, Calle EE (2005). Obesity, recreational physical activity, and risk of pancreatic cancer in a large U.S. cohort. *Cancer Epidemiol Biomarkers Prev*, 14(2):459–66. doi:[10.1158/1055-9965.EPI-04-0583](https://doi.org/10.1158/1055-9965.EPI-04-0583) PMID:[15734973](https://pubmed.ncbi.nlm.nih.gov/15734973/)
- Pezzilli R, Morselli-Labate AM, Migliori M, Manca M, Bastagli L, Gullo L (2005). Obesity and the risk of pancreatic cancer: an Italian multicenter study. *Pancreas*, 31(3):221–4. doi:[10.1097/01.mpa.0000175163.42327.91](https://doi.org/10.1097/01.mpa.0000175163.42327.91) PMID:[16163052](https://pubmed.ncbi.nlm.nih.gov/16163052/)
- Renehan AG, Tyson M, Egger M, Heller RF, Zwahlen M (2008). Body-mass index and incidence of cancer: a systematic review and meta-analysis of prospective observational studies. *Lancet*, 371(9612):569–78. doi:[10.1016/S0140-6736\(08\)60269-X](https://doi.org/10.1016/S0140-6736(08)60269-X) PMID:[18280327](https://pubmed.ncbi.nlm.nih.gov/18280327/)
- Samanic C, Chow WH, Gridley G, Jarvholm B, Fraumeni JF Jr (2006). Relation of body mass index to cancer risk in 362,552 Swedish men. *Cancer Causes Control*, 17(7):901–9. doi:[10.1007/s10552-006-0023-9](https://doi.org/10.1007/s10552-006-0023-9) PMID:[16841257](https://pubmed.ncbi.nlm.nih.gov/16841257/)
- Samanic C, Gridley G, Chow WH, Lubin J, Hoover RN, Fraumeni JF Jr (2004). Obesity and cancer risk among white and black United States veterans. *Cancer Causes Control*, 15(1):35–43. doi:[10.1023/B:CACO.0000016573.79453.ba](https://doi.org/10.1023/B:CACO.0000016573.79453.ba) PMID:[14970733](https://pubmed.ncbi.nlm.nih.gov/14970733/)
- Silverman DT (2001). Risk factors for pancreatic cancer: a case-control study based on direct interviews. *Teratog Carcinog Mutagen*, 21(1):7–25. doi:[10.1002/1520-6866\(2001\)21:1<7::AID-TCM3>3.0.CO;2-A](https://doi.org/10.1002/1520-6866(2001)21:1<7::AID-TCM3>3.0.CO;2-A) PMID:[11135318](https://pubmed.ncbi.nlm.nih.gov/11135318/)
- Silverman DT, Swanson CA, Gridley G, Wacholder S, Greenberg RS, Brown LM, et al. (1998). Dietary and nutritional factors and pancreatic cancer: a case-control study based on direct interviews. *J Natl Cancer Inst*, 90(22):1710–9. doi:[10.1093/jnci/90.22.1710](https://doi.org/10.1093/jnci/90.22.1710) PMID:[9827525](https://pubmed.ncbi.nlm.nih.gov/9827525/)
- Sinner PJ, Schmitz KH, Anderson KE, Folsom AR (2005). Lack of association of physical activity and obesity with incident pancreatic cancer in elderly women. *Cancer Epidemiol Biomarkers Prev*, 14(6):1571–3. doi:[10.1158/1055-9965.EPI-05-0036](https://doi.org/10.1158/1055-9965.EPI-05-0036) PMID:[15941975](https://pubmed.ncbi.nlm.nih.gov/15941975/)
- Sirri E, Castro FA, Kieschke J, Jansen L, Emrich K, Gondos A, et al. (2016). Recent trends in survival of patients with pancreatic cancer in Germany and the United States. *Pancreas*, 45(6):908–14. doi:[10.1097/MPA.0000000000000588](https://doi.org/10.1097/MPA.0000000000000588) PMID:[26745860](https://pubmed.ncbi.nlm.nih.gov/26745860/)
- Stevens RJ, Roddam AW, Spencer EA, Pirie KL, Reeves GK, Green J, et al.; Million Women Study Collaborators (2009). Factors associated with incident and fatal pancreatic cancer in a cohort of middle-aged women. *Int J Cancer*, 124(10):2400–5. doi:[10.1002/ijc.24196](https://doi.org/10.1002/ijc.24196) PMID:[19165860](https://pubmed.ncbi.nlm.nih.gov/19165860/)
- Stolzenberg-Solomon RZ, Adams K, Leitzmann M, Schairer C, Michaud DS, Hollenbeck A, et al. (2008). Adiposity, physical activity, and pancreatic cancer in the National Institutes of Health-AARP Diet and Health Cohort. *Am J Epidemiol*, 167(5):586–97. doi:[10.1093/aje/kwm361](https://doi.org/10.1093/aje/kwm361) PMID:[18270373](https://pubmed.ncbi.nlm.nih.gov/18270373/)
- Stolzenberg-Solomon RZ, Schairer C, Moore S, Hollenbeck A, Silverman DT (2013). Lifetime adiposity and risk of pancreatic cancer in the NIH-AARP Diet and Health Study cohort. *Am J Clin Nutr*, 98(4):1057–65. doi:[10.3945/ajcn.113.058123](https://doi.org/10.3945/ajcn.113.058123) PMID:[23985810](https://pubmed.ncbi.nlm.nih.gov/23985810/)
- Untawale S, Odegaard AO, Koh WP, Jin AZ, Yuan JM, Anderson KE (2014). Body mass index and risk of pancreatic cancer in a Chinese population. *PLoS ONE*, 9(1):e85149. doi:[10.1371/journal.pone.0085149](https://doi.org/10.1371/journal.pone.0085149) PMID:[24454807](https://pubmed.ncbi.nlm.nih.gov/24454807/)
- Urayama KY, Holcatova I, Janout V, Foretova L, Fabianova E, Adamcakova Z, et al. (2011). Body mass index and body size in early adulthood and risk of pancreatic cancer in a central European multicenter case-control study. *Int J Cancer*, 129(12):2875–84. doi:[10.1002/ijc.25959](https://doi.org/10.1002/ijc.25959) PMID:[21520034](https://pubmed.ncbi.nlm.nih.gov/21520034/)
- Verhage BA, Schouten LJ, Goldbohm RA, van den Brandt PA (2007). Anthropometry and pancreatic cancer risk: an illustration of the importance of microscopic verification. *Cancer Epidemiol Biomarkers Prev*, 16(7):1449–54. doi:[10.1158/1055-9965.EPI-07-0201](https://doi.org/10.1158/1055-9965.EPI-07-0201) PMID:[17585056](https://pubmed.ncbi.nlm.nih.gov/17585056/)
- WCRF/AICR (2012). Continuous Update Project Report. Diet, nutrition, physical activity and pancreatic cancer. Available from: <https://www.wcrf.org/sites/default/files/Pancreatic-cancer-report.pdf>.

- Whitlock G, Lewington S, Sherliker P, Clarke R, Emberson J, Halsey J, et al.; Prospective Studies Collaboration (2009). Body-mass index and cause-specific mortality in 900 000 adults: collaborative analyses of 57 prospective studies. *Lancet*, 373(9669):1083–96. doi:[10.1016/S0140-6736\(09\)60318-4](https://doi.org/10.1016/S0140-6736(09)60318-4) PMID:[19299006](https://pubmed.ncbi.nlm.nih.gov/19299006/)
- Zheng Z, Zheng R, He Y, Sun X, Wang N, Chen T, et al. (2016). Risk factors for pancreatic cancer in China: a multicenter case-control study. *J Epidemiol*, 26(2):64–70. doi:[10.2188/jea.JE20140148](https://doi.org/10.2188/jea.JE20140148) PMID:[26441209](https://pubmed.ncbi.nlm.nih.gov/26441209/)